ReCell approved in China
Thursday, 03 July, 2008
The Chinese State Food and Drug Administration (SFDA) has granted approval to register Avita Medical's (ASX: AVH) ReCell cell harvesting device on the Chinese market.
The product will be marketed by Helicon Group (ASX: HCG), a WA-headquartered pharmaceutical marketing company specialising in introducing registered medical products into niche markets in China.
The SFDA has approved the product concept and the ReCell kit, but Helicon said there were some importation issues to be overcome before it is on the market.
Helicon has also recently acquired the exclusive licensing rights from EUSA Pharma for Collatamp, an implantable collagen device for the delivery of antibiotics to surgical sites, and is preparing a submission to the SFDA for registration.
Avita Medical was formerly known as Clinical Cell Culture.
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
